Purpose of Review
Allergen immunotherapy has been used for over 100 years in the treatment of allergic rhinitis. With two major options for administering this disease-modifying therapy, SCIT, and SLIT, what is our current understanding of the efficacy and safety of each one? How do we determine who is the appropriate candidate for each one in the real world?
SCIT and SLIT show significant improvement in clinical symptoms and need for medication in the treatment of allergic rhinitis. In recent meta-analyses, there is no significant difference in the efficacy between the two treatments, but SLIT has more local side effects though less systemic ones. Shared decision-making should be instituted to determine which treatment should be started in a patient with allergic rhinitis.
This review provides up-to-date information on the efficacy and safety of SCIT vs SLIT in the care of children and adults with allergic rhinitis in the real world and the role of shared decision-making in the use of these modalities.
Clinicaltrials.gov: NCT04145219 and NCT02478398
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Papers of particular interest, published recently, have been highlighted as:•• Of major importance
Cohen SG, Richard E 3rd. Allergen immunotherapy in historical perspective. Clin Allergy Immunol. 2008;21:1–29.
Fitzhugh DJ, Lockey RF. Allergen immunotherapy: a history of the first 100 years. Curr Opin Allergy Clin Immunol. 2011;11(6):554–9. https://doi.org/10.1097/ACI.0b013e32834c3134.
Frankland AW, Augustin R. Prophylaxis of summer hay-fever and asthma: a controlled trial comparing crude grass-pollen extracts with the isolated main protein component. Lancet. 1954;266(6821):1055–7. https://doi.org/10.1016/s0140-6736(54)91620-7.
Durham SR, Nelson H. Allergen immunotherapy: a centenary celebration. World Allergy Organ J. 2011;4(6):104–6. https://doi.org/10.1097/WOX.0b013e3182218920.
Passalacqua G, Bagnasco D, Canonica GW. 30 years of sublingual immunotherapy. Allergy. 2019. https://doi.org/10.1111/all.14113.
•• Globinska A, Boonpiyathad T, Satitsuksanoa P, Kleuskens M, van de Veen W, Sokolowska M, et al. Mechanisms of allergen-specific immunotherapy: diverse mechanisms of immune tolerance to allergens. Ann Allergy Asthma Immunol. 2018;121(3):306–12. https://doi.org/10.1016/j.anai.2018.06.026This update gives an excellent review of the diverse mechanisms of allergen immunotherapy and provides an insight into alternative routes of administration.
Palomares O, Akdis M, Martin-Fontecha M, Akdis CA. Mechanisms of immune regulation in allergic diseases: the role of regulatory T and B cells. Immunol Rev. 2017;278(1):219–36. https://doi.org/10.1111/imr.12555.
Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev. 2007(1):Cd001936. https://doi.org/10.1002/14651858.CD001936.pub2.
Rondon C, Blanca-Lopez N, Campo P, Mayorga C, Jurado-Escobar R, Torres MJ, et al. Specific immunotherapy in local allergic rhinitis: a randomized, double-blind placebo-controlled trial with Phleum pratense subcutaneous allergen immunotherapy. Allergy. 2018;73(4):905–15. https://doi.org/10.1111/all.13350.
Huang Y, Wang C, Cao F, Zhao Y, Lou H, Zhang L. Comparison of Long-term efficacy of subcutaneous immunotherapy in pediatric and adult patients with allergic rhinitis. Allergy, Asthma Immunol Res. 2019;11(1):68–78. https://doi.org/10.4168/aair.2019.11.1.68.
Song Y, Long J, Wang T, Xie J, Wang M, Tan G. Long-term efficacy of standardised specific subcutaneous immunotherapy in children with persistent allergic rhinitis due to multiple allergens including house dust mites. J Laryngol Otol. 2018;132(3):230–5. https://doi.org/10.1017/s0022215117002547.
Huang Y, Wang C, Wang X, Zhang L, Lou H. Efficacy and safety of subcutaneous immunotherapy with house dust mite for allergic rhinitis: a meta-analysis of randomized controlled trials. Allergy. 2019;74(1):189–92. https://doi.org/10.1111/all.13583.
Mustafa SS, Bingemann T, Blue H, Conn K, Hanley T, Ramsey A. Systemic reactions to subcutaneous immunotherapy: effects of dosing and aeroallergen content. Ann Allergy Asthma Immunol. 2019;123(3):284–7. https://doi.org/10.1016/j.anai.2019.06.021.
Epstein TG, Liss GM, Murphy-Berendts K, Bernstein DI. Risk factors for fatal and nonfatal reactions to subcutaneous immunotherapy: National surveillance study on allergen immunotherapy (2008–2013). Ann Allergy Asthma Immunol. 2016;116(4):354–9.e2. https://doi.org/10.1016/j.anai.2016.02.001.
Pfaar O, Lou H, Zhang Y, Klimek L, Zhang L. Recent developments and highlights in allergen immunotherapy. Allergy. 2018;73(12):2274–89. https://doi.org/10.1111/all.13652.
Epstein TG, Liss GM, Berendts KM, Bernstein DI. AAAAI/ACAAI Subcutaneous immunotherapy surveillance study (2013–2017): Fatalities, infections, delayed reactions, and use of epinephrine autoinjectors. J Allergy Clin Immunol Pract. 2019;7(6):1996–2003.e1. https://doi.org/10.1016/j.jaip.2019.01.058.
Cox LS. Sublingual immunotherapy: historical perspective and practical guidance. J Allergy Clin Immunol Pract. 2017;5(1):63–5. https://doi.org/10.1016/j.jaip.2016.11.016.
Tankersley M, Han JK, Nolte H. Clinical aspects of sublingual immunotherapy tablets and drops. Ann Allergy Asthma Immunol. 2020. https://doi.org/10.1016/j.anai.2019.12.025.
Tucker MH, Tankersley MS. Perception and practice of sublingual immunotherapy among practicing allergists. Ann Allergy Asthma Immunol. 2008;101(4):419–25. https://doi.org/10.1016/s1081-1206(10)60320-1.
•• Sivam A, Tankersley M. Perception and practice of sublingual immunotherapy among practicing allergists in the United States: A follow-up survey. Ann Allergy Asthma Immunol. 2019;122(6):623–9.e2. https://doi.org/10.1016/j.anai.2019.03.023This survey shows the uptake by Board-Certified allergists in using SLIT with FDA approved products and barriers for increased use.
Swamy RS, Reshamwala N, Hunter T, Vissamsetti S, Santos CB, Baroody FM, et al. Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy. J Allergy Clin Immunol. 2012;130(1):215–24.e7. https://doi.org/10.1016/j.jaci.2012.04.021.
Creticos PS, Esch RE, Couroux P, Gentile D, D'Angelo P, Whitlow B, et al. Randomized, double-blind, placebo-controlled trial of standardized ragweed sublingual-liquid immunotherapy for allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2014;133(3):751–8. https://doi.org/10.1016/j.jaci.2013.10.041.
Mosges R, Breitruck NY, Allekotte S, Shah-Hosseini K, Dao VA, Zieglmayer P, et al. Shortened up-dosing with sublingual immunotherapy drops containing tree allergens is well tolerated and elicits dose-dependent clinical effects during the first pollen season. World Allergy Organ J. 2019;12(2):100012. https://doi.org/10.1016/j.waojou.2019.100012.
Nelson HS, Nolte H, Creticos P, Maloney J, Wu J, Bernstein DI. Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. J Allergy Clin Immunol. 2011;127(1):72–80, .e1-2. https://doi.org/10.1016/j.jaci.2010.11.035.
Blaiss M, Maloney J, Nolte H, Gawchik S, Yao R, Skoner DP. Efficacy and safety of timothy grass allergy immunotherapy tablets in north American children and adolescents. J Allergy Clin Immunol. 2011;127(1):64–71, .e1-4. https://doi.org/10.1016/j.jaci.2010.11.034.
Maloney J, Bernstein DI, Nelson H, Creticos P, Hebert J, Noonan M, et al. Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial. Ann Allergy Asthma Immunol. 2014;112(2):146–53.e2. https://doi.org/10.1016/j.anai.2013.11.018.
Nolte H, Bernstein DI, Nelson HS, Kleine-Tebbe J, Sussman GL, Seitzberg D, et al. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2016;138(6):1631–8. https://doi.org/10.1016/j.jaci.2016.06.044.
Masuyama K, Okamoto Y, Okamiya K, Azuma R, Fujinami T, Riis B, et al. Efficacy and safety of SQ house dust mite sublingual immunotherapy-tablet in Japanese children. Allergy. 2018;73(12):2352–63. https://doi.org/10.1111/all.13544.
Okamoto Y, Fujieda S, Okano M, Hida H, Kakudo S, Masuyama K. Efficacy of house dust mite sublingual tablet in the treatment of allergic rhinoconjunctivitis: a randomized trial in a pediatric population. Pediatr Allergy Immunol. 2019;30(1):66–73. https://doi.org/10.1111/pai.12984.
Didier A, Malling HJ, Worm M, Horak F, Sussman GL. Prolonged efficacy of the 300IR 5-grass pollen tablet up to 2 years after treatment cessation, as measured by a recommended daily combined score. Clin Transl Allergy. 2015;5:12. https://doi.org/10.1186/s13601-015-0057-8.
Durham SR, Emminger W, Kapp A, de Monchy JG, Rak S, Scadding GK, et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol. 2012;129(3):717–25.e5. https://doi.org/10.1016/j.jaci.2011.12.973.
Nolte H, Maloney J. The global development and clinical efficacy of sublingual tablet immunotherapy for allergic diseases. Allergol Int. 2018;67(3):301–8. https://doi.org/10.1016/j.alit.2018.03.008.
Valovirta E, Petersen TH, Piotrowska T, Laursen MK, Andersen JS, Sorensen HF, et al. Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy. J Allergy Clin Immunol. 2018;141(2):529–38.e13. https://doi.org/10.1016/j.jaci.2017.06.014.
Halken S, Roberts G, Valovirta E, Nolte H, Hulstrom V, Blaiss MS. Safety of timothy grass sublingual immunotherapy tablet in children: pooled analyses of clinical trials. J Allergy Clin Immunol Pract. 2020;8:1387–1393.e2. https://doi.org/10.1016/j.jaip.2020.01.008.
•• James C, Bernstein DI. Allergen immunotherapy: an updated review of safety. Curr Opin Allergy Clin Immunol. 2017;17(1):55–9. https://doi.org/10.1097/aci.0000000000000335Excellent review discussing safety of allergen immunotherapy emphasizing low risk of anaphylaxis with SCIT and local reactions due to SLIT.
Tang LX, Yang XJ, Wang PP, Ge WT, Zhang J, Guo YL, et al. Efficacy and safety of sublingual immunotherapy with Dermatophagoides farinae drops in pre-school and school-age children with allergic rhinitis. Allergol Immunopathol (Madr). 2018;46(2):107–11. https://doi.org/10.1016/j.aller.2017.09.022.
Zhang YZ, Luo J, Wang ZH, Wang J. Efficacy and safety of sublingual dust mite drops in children with mono- or polysensitized allergic rhinitis. Am J Otolaryngol. 2019;40(5):755–60. https://doi.org/10.1016/j.amjoto.2019.07.010.
Zhong C, Yang W, Li Y, Zou L, Deng Z, Liu M, et al. Clinical evaluation for sublingual immunotherapy with Dermatophagoides farinae drops in adult patients with allergic asthma. Ir J Med Sci. 2018;187(2):441–6. https://doi.org/10.1007/s11845-017-1685-x.
Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev. 2010;(12):Cd002893. https://doi.org/10.1002/14651858.Cd002893.
Epstein TG, Calabria C, Cox LS, Dreborg S. Current evidence on safety and practical considerations for administration of sublingual allergen immunotherapy (SLIT) in the United States. J Allergy Clin Immunol Pract. 2017;5(1):34–40.e2. https://doi.org/10.1016/j.jaip.2016.09.017.
Casale TB, Canonica GW, Bousquet J, Cox L, Lockey R, Nelson HS, et al. Recommendations for appropriate sublingual immunotherapy clinical trials. J Allergy Clin Immunol. 2009;124(4):665–70. https://doi.org/10.1016/j.jaci.2009.07.054.
Bernstein DI, Bardelas JA Jr, Svanholm Fogh B, Kaur A, Li Z, Nolte H. A practical guide to the sublingual immunotherapy tablet adverse event profile: implications for clinical practice. Postgrad Med. 2017;129(6):590–7. https://doi.org/10.1080/00325481.2017.1302306.
•• Dhami S, Nurmatov U, Arasi S, Khan T, Asaria M, Zaman H, et al. Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and meta-analysis. Allergy. 2017;72(11):1597–631. https://doi.org/10.1111/all.13201A definitive review and meta-analysis by the European Academy of Allergy and Clinical Immunology showing efficacy of allergen immunotherapy while on treatment and data suggesting sustained effect on discontinuation of therapy.
Kristiansen M, Dhami S, Netuveli G, Halken S, Muraro A, Roberts G, et al. Allergen immunotherapy for the prevention of allergy: a systematic review and meta-analysis. Pediatr Allergy Immunol. 2017;28(1):18–29. https://doi.org/10.1111/pai.12661.
Di Bona D, Plaia A, Leto-Barone MS, La Piana S, Macchia L, Di Lorenzo G. Efficacy of allergen immunotherapy in reducing the likelihood of developing new allergen sensitizations: a systematic review. Allergy. 2017;72(5):691–704. https://doi.org/10.1111/all.13104.
Chaaban MR, Mansi A, Tripple JW, Wise SK. SCIT Versus SLIT: which one do you recommend, doc? Am J Med Sci. 2019;357(5):442–7. https://doi.org/10.1016/j.amjms.2019.02.004.
Nelson HS. Subcutaneous immunotherapy versus sublingual immunotherapy: which is more effective? J Allergy Clin Immunol Pract. 2014;2(2):144–9; quiz 50-1. https://doi.org/10.1016/j.jaip.2013.11.018.
Durham SR, Penagos M. Sublingual or subcutaneous immunotherapy for allergic rhinitis? J Allergy Clin Immunol. 2016;137(2):339–49.e10. https://doi.org/10.1016/j.jaci.2015.12.1298.
Quirino T, Iemoli E, Siciliani E, Parmiani S, Milazzo F. Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study. Clin Exp Allergy. 1996;26(11):1253–61.
Khinchi MS, Poulsen LK, Carat F, Andre C, Hansen AB, Malling HJ. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy. 2004;59(1):45–53. https://doi.org/10.1046/j.1398-9995.2003.00387.x.
Ventura MT, Carretta A, Tummolo RA, Buquicchio R, Arsieni A, Murgia N. Clinical data and inflammation parameters in patients with cypress allergy treated with sublingual swallow therapy and subcutaneous immunotherapy. Int J Immunopathol Pharmacol. 2009;22(2):403–13. https://doi.org/10.1177/039463200902200217.
Yukselen A, Kendirli SG, Yilmaz M, Altintas DU, Karakoc GB. Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebo-controlled, double-blind, double-dummy study. Int Arch Allergy Immunol. 2012;157(3):288–98. https://doi.org/10.1159/000327566.
•• Blaiss MS, Steven GC, Bender B, Bukstein DA, Meltzer EO, Winders T. Shared decision making for the allergist. Ann Allergy Asthma Immunol. 2019;122(5):463–70. https://doi.org/10.1016/j.anai.2018.08.019An excellent review on how shared decision making works and provide practical advice and allergist-specific shared decision making resources.
American Academy of Allergy Asthma and Immunology. Should I treat my allergies with immunotherapy? 2020. http://allergyrelief.acaai.org/. Accessed 1 Apr 2020.
Jutel M, Agache I, Bonini S, Burks AW, Calderon M, Canonica W, et al. International consensus on allergen immunotherapy II: mechanisms, standardization, and pharmacoeconomics. J Allergy Clin Immunol. 2016;137(2):358–68. https://doi.org/10.1016/j.jaci.2015.12.1300.
Wang T, Li Y, Wang F, Zhou C. Nonadherence to sublingual immunotherapy in allergic rhinitis: a real-life analysis. Int Forum Allergy Rhinol. 2017;7(4):389–92. https://doi.org/10.1002/alr.21909.
Conflict of Interest
Michael S. Blaiss, MD, has received honorarium for consulting for ALK and Stallergenes/Greer. No other authors have any conflict of interest relevant to this manuscript.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is part of the Topical Collection on Immunotherapy and Immunomodulators
Rights and permissions
About this article
Cite this article
Field, K., Blaiss, M.S. Sublingual Versus Subcutaneous Immunotherapy for Allergic Rhinitis: What Are the Important Therapeutic and Real-World Considerations?. Curr Allergy Asthma Rep 20, 45 (2020). https://doi.org/10.1007/s11882-020-00934-4
- Subcutaneous immunotherapy
- Sublingual immunotherapy
- Allergen immunotherapy
- Allergic rhinitis
- Shared decision making